Researchers at the University of Houston (UH) said the findings raise hope for a new class of drugs to treat lupus that may not include the long list of adverse risks and side effects often associated with current treatments for this disease.
Lupus, or systemic lupus erythematosus, has symptoms ranging from debilitating pain and fatigue to organ failure and a host of other impairments.
An estimated 1.5 million Americans, and at least five million people worldwide, have a form of lupus.
By suppressing the immune system in its entirety, however, this mode of treatment carries with it an increased risk of infections and other harmful side effects.
Chandra Mohan, Hugh Roy and Lillie Cranz Cullen Endowed Professor of biomedical engineering in the UH Cullen College of Engineering, and his group said that the use of a synthetic, plant-derived compound - abbreviated CDDO - was shown to effectively suppress the multiple steps of lupus development in murine models, including the onset of kidney disease.
Lupus nephritis, which causes inflammation of the kidneys and impairs their ability to effectively rid the body of waste products and other toxins, is the leading cause of lupus-related deaths and results in tens of thousands of hospitalisations per year.
"The development of lupus is a two-step reaction. First, the immune system develops antibodies that attack the body's own DNA, then that activated immune system attacks the kidneys. We found that CDDO may block both of these steps," Mohan said.
"The most exciting part of this research is that CDDO is originally plant-derived, so it's relatively natural and carries less chance of side effects.
"Additionally, compared to many other test compounds we've previously tried for treating lupus, this one appears to be much more effective," Mohan said.
